Mycophenolate mofetil (MMF) is the ester prodrug of the immunosuppressant agent mycophenolic acid (MPA) and is rapidly activated by esterases after oral administration. However, the role of isoenzymes in MMF hydrolysis remains unclear. Although human plasma, erythrocytes, and whole blood contain MMF hydrolytic activities, the mean half-lives of MMF in vitro were 15.1, 1.58, and 3.20 h, respectively. Thus, blood esterases seemed to contribute little to the rapid MMF disappearance in vivo. In vitro analyses showed that human intestinal microsomes exposed to 5 
Introduction
Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF) (Fig. 1) , is a noncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase and therefore inhibits the de novo pathway of guanine nucleotide synthesis. Because T-and B-lymphocytes are dependent on de novo purine synthesis for proliferation, MPA has a cytostatic effect on lymphocytes (Allison and Eugui, 1993) .
MMF was designed to improve MPA bioavailability as an estertype oral prodrug. The oral bioavailability of MPA after MMF administration is reported to be 80.7 to 94% (Bullingham et al., 1998; Pescovitz et al., 2000; Staatz and Tett 2007) , such that MMF is essentially completely hydrolyzed to MPA by esterases (Bullingham et al., 1998) . Because MMF was almost completely absent in plasma from patients with renal transplants (Bullingham et al., 1996; Armstrong et al., 2005) , the conversion from MMF to the active form MPA is considered to occur rapidly in the blood, intestine, and liver, after gastrointestinal absorption (Lee et al., 1990) .
Esterases in the blood, intestine, and liver play important roles in drug metabolism and detoxication (Satoh et al., 2002) . Butylcholinesterase in plasma, arylesterase, and carboxylesterase (CES) 1 in the erythrocyte cytosol and acetylcholinesterase in the erythrocyte membrane have been described previously (La Du and Snady, 1971; Ott et al., 1975; Oertel et al., 1983) . Human intestine and liver tissues express mainly CES2 and CES1/CES2, respectively, and CES expression in both intestine and liver is extremely high compared with that in other organs (Satoh et al., 2002) . CESs play central roles in the hydrolysis and bioactivation of various drugs, including cocaine, heroin and irinotecan (Pindel et al., 1997; Slatter et al., 1997) . In addition, CES1 and CES2 expressed in the liver cytosol are reported to be required for the bioactivation of irinotecan and capecitabine (Xu et al., 2002; Tabata et al., 2004a,b) .
Glucuronidation is an important phase II metabolic pathway for MPA, and the molecular mechanisms underlying this process have been demonstrated by various researchers (Bernard and internal standard, and the solutions were vortexed for 30 s and then centrifuged for 10 min at 3000g. Aliquots of the clear supernatants were filtered through Millipore filters (0.45 m, Millex-LH; Nihon Millipore, Tokyo, Japan). The final concentration of organic solvent in all reaction mixtures was Ͻ1.0%. Samples were then directly injected into a high-performance liquid chromatography apparatus (AS-2057 plus intelligent sampler, PU-2080 plus chromatography pump, UV-2075 plus ultraviolet detector, and 807-IT integrator; JASCO, Tokyo, Japan) equipped with a CAPCELL PAK C18 MG II column (250 mm ϫ 4.6 mm, 5 m; Shiseido, Tokyo, Japan). The mobile phase was 0.5% KH 2 PO 4 (pH 3.5)-acetonitrile (1:1). Elution was performed at a flow rate of 0.5 ml/min. MPA was monitored at a wavelength of 254 nm, and the lower limit of MPA detection was 25 ng/ml.
In preliminary experiments, reaction conditions were confirmed to ensure initial rates of MPA formation. MPA enzymatic production rates were calculated by subtracting nonenzymatic production rates obtained after incubation without added enzyme sources.
Inhibition Studies. Inhibitory effects on the hydrolysis of MMF to MPA were evaluated using the inhibitors DFP, BNPP, and PMSF. Inhibitors were preincubated with human tissue fractions at 37°C for 1 min to give final inhibitor concentrations of 0.001 to 10 M (DFP), 0.01 to 100 M (BNPP), and 0.1 to 1000 M (PMSF). Reactions were started by the addition of MMF solution, and the MMF levels were quantitated in reactions containing 12.5 M liver fractions, 25 M intestine fractions, or S9 fractions from COS-1 cells expressing human CES1 or CES2.
Data Analysis. MMF concentration-time data obtained from MPA production reactions were fitted to the equation [C(t) ϭ Ae Ϫat ] using SigmaPlot 9.0 software (HULINKS Inc., Tokyo, Japan). Velocity versus MMF concentration plots were fitted to the Michaelis-Menten equation (one-or two-site saturation models) by nonlinear least-squares regression analysis using SigmaPlot 9.0 software). IC 50 values were calculated by nonlinear least-squares regression analysis using SigmaPlot 9.0 software.
Statistical Analysis. Statistical analyses were performed using an unpaired t test or one-way analysis of variance followed by Dunnett's test using InStat 3 software (GraphPad Software, Inc., San Diego, CA). P Ͻ 0.05 was considered statistically significant.
Results

MMF Hydrolysis to MPA in Human Blood
Fractions. MMF hydrolysis in human blood samples was evaluated in vitro. MPA formation from nonenzymatic MMF hydrolysis after 10, 45, 90, and 135 min of incubation was 0.35, 1.11, 2.02, and 3.15%, respectively, using 100 M MMF in 100 mM phosphate buffer without the addition of enzyme sources. As shown in Fig. 2 , whole blood, erythrocytes, and plasma formed MPA from MMF time dependently. The elimination rate constants (k el ) of MMF in whole blood, erythrocytes, and plasma were 0.24 Ϯ 0.11, 0.46 Ϯ 0.11, and 0.051 Ϯ 0.015 h Ϫ1 , respectively, giving corresponding MMF half-lives (t 1/2 ) of 3.2 Ϯ 0.94, 1.6 Ϯ 0.43, and 15 Ϯ 6.1 h, respectively (Table 1 ). The half-life of MMF in whole blood was approximately 2-fold longer than that in erythrocytes, whereas the plasma MMF half-life was approximately 10-fold longer than that in erythrocytes.
MMF Hydrolysis to MPA in Human Tissue Fractions. To calculate the kinetic parameters of MPA formation from MMF, MMF was incubated with HIM, HJC, HIC, HLM, and HLC (Fig. 3) . In preliminary experiments, reaction conditions were confirmed to ensure that the initial rates of MPA formation were optimal for each protein concentration and each reaction time, as described under Materials and Methods. Velocity versus MMF concentration plots for HIM, HJC, and HIC are shown in Fig. 3 , A to C, with the three data plots best fitted to a two-site saturation model. Typical Eadie-Hofstee plots of MPA formed from MMF in the presence of HIM, HJC, and HIC were clearly biphasic as shown in the insets to Fig. 3 . The kinetic parameters of MPA formation from MMF are shown in Table 2 . For HIM, the estimated apparent K m , V max , and intrinsic clearance (Cl int ; V max /K m ) values were 27.3 Ϯ 4.7 M, 15.6 Ϯ 1.5 nmol/(min ⅐ mg protein), and 571 l/(min ⅐ mg protein), respectively, for the highaffinity enzyme reaction and 782 Ϯ 256 M, 19.7 Ϯ 1.2 nmol/(min ⅐ mg protein), and 252 l/(min ⅐ mg protein), respectively, for the low-affinity enzyme reaction. For HJC, the estimated apparent K m , V max , and Cl int values for MPA formation were 14.9 Ϯ 5.4 M, 4.58 Ϯ 0.72 nmol/(min ⅐ mg protein), and 307 l(min ⅐ mg protein), respectively, for the high-affinity enzyme reaction and 1091 Ϯ 432 M, 14.2 Ϯ 1.76 nmol/(min ⅐ mg protein), and 13 l/(min ⅐ mg protein), respectively, for the low-affinity enzyme reaction. For HIC, the estimated apparent K m , V max , and Cl int values for MPA formation were 17.5 Ϯ 6.0 M, 5.94 Ϯ 0.84 nmol/(min ⅐ mg protein), and 339 l/(min ⅐ mg protein), respectively, for the high-affinity enzyme reaction and 1656 Ϯ 1355 M, 12.0 Ϯ 4.2 nmol/(min ⅐ mg protein), and 7 l/(min ⅐ mg protein), respectively, for the low-affinity enzyme reaction.
Velocity versus MMF concentration plots obtained using HLM and HLC are shown in Fig. 3, D and E, respectively, and the data were best fitted to a one-site saturation model. The estimated apparent K m and V max values for MPA formation using HLM were 992 Ϯ 69 M and 3072 Ϯ 112 nmol/(min ⅐ mg protein), respectively ( Table 2) MMF Hydrolysis by Recombinant Human CES1 and CES2. Levels of MPA formation in S9 fractions from COS-1 cells expressing human CES1 or CES2 after MMF incubation are shown in Fig. 4A . Hydrolytic activities on 100 M MMF in response to the negative control, hCES1, and hCES2 were 0.51 Ϯ 0.16, 83.6 Ϯ 6.2, and 7.98 Ϯ 0.43 nmol/(min ⅐ mg protein), respectively. COS-1 CES1 and CES2 S9 fractions had significantly higher MMF hydrolytic activities compared with that for the negative control. To characterize MMF hydrolysis by CES1 and CES2, kinetic parameters were calculated from velocity versus MMF concentration plots, as shown in Fig. 4 , B and a Kinetic parameters were obtained from our previous report (Fujiyama et al, 2009 ).
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C. In both cases, data best fitted to a one-site saturation model. The estimated K m , V max , and Cl int values for MPA formation were 225 Ϯ 12 M, 313 Ϯ 5 nmol/(min ⅐ mg protein), and 1391 l/(min ⅐ mg protein), respectively, for hCES1 and 22.3 Ϯ 2.1 M, 12.3 Ϯ 0.2 nmol/(min ⅐ mg protein), and 552 l/(min ⅐ mg protein), respectively, for hCES2 (Table 3) .
Effects of CES Inhibitors on MMF Hydrolysis to MPA.
Inhibitory effects of DFP, BNPP, and PMSF on MMF hydrolysis in the presence of HIM, HJC, HIC, HLM, HLC, hCES1, and hCES2 are shown in Fig. 5 , A to G. MPA formation from all enzymatic sources was inhibited by DFP, BNPP, and PMSF in concentration-dependent manners, except for DFP and BNPP inhibition of MPA formation by HIM. Residual MMF hydrolytic activities in HIM in the presence of 10 M DFP and 100 M BNPP were 14.2 and 12.8% of control values, respectively (Fig. 4A) . The estimated IC 50 values for inhibitory effects as determined from these residual activities are shown in Table 4 . Inhibitory effects on MMF hydrolysis by DFP, BNPP, and PMSF were stronger in HLC than in HLM, and the effects of DFP and BNPP were stronger on hCES2 than on hCES1.
Discussion
Several reports have found that the pharmacokinetics of MPA in humans is characterized by large inter-and intraindividual variability and that glucuronide activity from MPA may be involved in the between-individual variability (Kuypers et al., 2005; Baldelli et al., 2007) . In the present study, we focused on the importance of the MMF bioactivation pathway to MPA as a factor other than the MPA glucuronidation pathway previously researched.
At 10 min after peripheral intravenous infusion with MMF, plasma MMF concentrations fall below detection levels in human test subjects, which led to the conclusion that the half-life of MMF in human plasma in vivo was approximately 2 min (Bullingham et al., 1996) . However, in the present in vitro study, the estimated mean half-life of MMF in plasma was 15.1 and 1.58 h in erythrocytes. Because the measured mean hematocrit value was 0.468 Ϯ 0.053, esterases located in erythrocytes seemed to be involved in MMF hydrolysis. However, the half-life of MMF in human blood in vitro was much longer than that reported in a previous in vivo study (Bullingham et al., 1996) . This finding suggests that blood esterases contribute little to the rapid disappearance of MMF in the human body and that gastrointestinal organs and the liver may be central to MMF hydrolysis.
Our study found that the order of MMF to MPA hydrolysis rate was liver Ͼ Ͼ intestine, with HLM showing the highest MMF hydrolytic activity [Cl int for MPA formation in the presence of HLM being 3098 nl/(min ⅐ mg protein)]. However, our previous study gave an intrinsic clearance value for HLM of 1308 nl/(min ⅐ mg protein) (Fujiyama et al., 2009 ). The HLM used in the present and previous studies were supplied by BD and consisted of microsomes pooled from 33 and 27 donors, respectively. Because microsomal carboxylesterase activity can exhibit large interindividual variations, the difference in HLM activities between our studies could be due to chance differences in assay validation. The Cl int for MMF hydrolysis in response to enzymes from intestinal tissues was 5-fold lower than that from liver cellular fractions. It is known that the intestine predominantly expresses the CES2 isoform rather than CES1 (Satoh et al., 2002; Taketani et al., 2007) . Therefore, it is possible that the MMF hydro- 
Kinetic parameters of MMF hydrolysis in S9 from COS-1 cells expressing CES1 and CES2
Values are represented as mean (S.D.). lytic activity in hepatic fractions was mainly due to CES1, as the liver highly expresses both CES1 and CES2. To clarify the role of CES isoforms in MMF hydrolysis, we examined recombinant human cells expressing CES1 or CES2. Hydrolytic activity on 100 M MMF by hCES1 was approximately 10-fold higher than that by hCES2, such that the Cl int for MPA formation by hCES1 was higher than that by hCES2 [1391 versus 552 nl/(min ⅐ mg protein)]. Thus, it appears that CES1 may be important for MPA formation. However, because orally administrated prodrugs encounter intestinal esterases before liver esterases, it is likely that some hydrolysis would still occur in the intestine (Fig. 6 ). Because CESs were reported to be expressed in the inner lumen of the endoplasmic reticulum (Robbi and Beaufay, 1987; Medda and Proia, 1992) , it was thought that only compounds located in the lumen underwent hydrolysis and glucuronidation. However, Tabata et al. (2004a) reported that CES1 is present in both microsomes and cytosols and that cytosolic CES plays an important role in the bioactivation of the prodrug, capecitabine. Because there is approximately 5-fold more total cytosolic protein than microsomal protein, when we extrapolated this to the results obtained in the present study, we estimated that cytosolic MMF hydrolysis was equivalent to approximately 37 or 88% of the microsomal MMF hydrolysis. This result is consistent with our finding that HLC showed 46 to 50% lower MMF hydrolytic activity than HLM over the concentration range of 5 to 10 M MMF. On the basis of these results, our study indicated that the order of MMF to MPA hydrolysis rates was HLM Ͼ HLC Ͼ HIM Ͼ HJC ϭ HIC. Moreover, although MMF has high membrane permeability, MMF hydrolysis in the cytosol may be decreased by formation of MPA glucuronide metabolites by uridine diphosphate glucuronosyltransferases located in the inner lumen of the endoplasmic reticulum because of the low membrane permeability of MPA. Therefore, cytosolic CESs may be an important determinant of MMF pharmacokinetics in vivo.
We further investigated the esterases involved in MMF hydrolysis in human samples using a series of inhibitors. In erythrocytes, the CES inhibitor BNPP (10 M) inhibited MMF hydrolysis by only 5.6% relative to control values, whereas the arylesterase inhibitor 5,5Ј-dithiobis(2-nitrobenzoic acid) showed no inhibition at all (Heymann and Krisch, 1967; Costello and Green, 1983) (supplemental data). Therefore, an erythrocyte esterase other than CES and arylesterase, namely acetylcholinesterase, seemed to be responsible for MMF hydrolysis in whole blood. In intestinal fractions, addition of DFP and BNPP to HIM inhibited MMF hydrolysis by 87% relative to control values. In theory, 92% of the hydrolysis of 25 M MMF by HIM was due to the high-affinity enzyme present in HIM. The kinetic parameters of MPA formation by the high-affinity enzyme in HIM were similar to the kinetics displayed by S9 fractions from COS-1 cells expressing CES2. Therefore, our results indicated that the HIM esterase involved in MMF hydrolysis is CES2. Although intestinal cytosolic fractions HJC and HIC also exhibited the biphasic curves, MMF hydrolysis in HJC and HIC was completely inhibited by BNPP. This result suggested that multiple CESs might be involved in this pathway. Moreover, to our knowledge, the existence of CESs in the intestinal cytosol has not been reported previously. Because both microsomal and cytosolic CESs appear to play key roles in first-pass effects on the esterified prodrug, further study on intestinal cytosolic CESs is required.
In conclusion, MMF was hydrolyzed by human intestinal and hepatic fractions rather than by human blood fractions. Although orally dosed MMF rapidly disappears from the blood, our results suggested that the disappearance of MMF was due mainly to hepatic CESs, in particular CES1. 
